Paradigm Biopharmaceuticals Ltd
ASX:PAR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Paradigm Biopharmaceuticals Ltd
Income from Continuing Operations
Paradigm Biopharmaceuticals Ltd
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Paradigm Biopharmaceuticals Ltd
ASX:PAR
|
Income from Continuing Operations
-AU$36.1m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Income from Continuing Operations
-$94.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Income from Continuing Operations
$1.4B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Income from Continuing Operations
-AU$9.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Income from Continuing Operations
-AU$7.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Income from Continuing Operations
-AU$48.3m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
-30%
|
|
Paradigm Biopharmaceuticals Ltd
Glance View
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.
See Also
What is Paradigm Biopharmaceuticals Ltd's Income from Continuing Operations?
Income from Continuing Operations
-36.1m
AUD
Based on the financial report for Dec 31, 2025, Paradigm Biopharmaceuticals Ltd's Income from Continuing Operations amounts to -36.1m AUD.
What is Paradigm Biopharmaceuticals Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-5%
Over the last year, the Income from Continuing Operations growth was -147%. The average annual Income from Continuing Operations growth rates for Paradigm Biopharmaceuticals Ltd have been 6% over the past three years , -5% over the past five years .
